Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether exemestane plus dasatinib will be
well-tolerated and will increase progression-free survival (PFS) in the treatment of advanced
estrogen-receptor positive (ER+) breast cancer after disease progression (PD) on a
non-steroidal aromatase inhibitor (NSAI).